You are here Biopharmaceutical/ Genomic Glossary Homepage/Search > >Pharmaceutical Applications guide & Site Map

21st century drug discovery & development glossaries & taxonomies Site map
Evolving Terminology for Emerging Technologies
Comments? Questions? Revisions? Mary Chitty  mchitty@healthtech.com
Last revised November 19, 2009
View a Printer-Friendly Version of this Web Page!

Not a comprehensive list of terms, but a quick and dirty finding aid while I'm working on getting these glossaries into a (long overdue) searchable database.
A to Z  index   Glossaries & Taxonomies Site Map   How to look for other unfamiliar  terms  Drug discovery & development Overview     Ethics

CHI’s Drug Discovery and Development Map    21st century drug discovery drug development & drug safety map

Biomarkers biological markers, biosignatures, bridging biomarkers, disease markers, efficacy biomarkers, genetic biomarkers, protein biomarkers, serum biomarkers, surrogate ... , type 0 biomarkers, type I biomarkers, type II biomarkers

Business of  biopharmaceuticals  attrition, benchmarking, best practices, big pharma, bioentrepreneur, biotechnology ..., blockbusters, business models, competitive ..., core competencies, deals, disintermediation, disruptive technologies, elevator pitch, FIPCO, franchises, GICS, genomics ...,  high tech industry, hypercompetitive, lead users, market ..., megabrands, multibusters, optimization, outpartnering, outsourcing, pharmaceutical ..., platform ..., price trends, productivity ..., proof of concept, proof of principle, portfolio, risk, sexy technologies, start-ups, technology ..., white space 
        Biopharmaceutical Alliances CRADA, collaboration..., consortium, deal..., expectations management, joint venture, keiretsu, licensing, pre- competitive, research joint venture, strategic ..., technology transfer
            Biopharmaceutical Finance A rounds, angel investor, burn rate, equity, opportunity costs, pharmacoeconomics, profit hunts, ROI return on investment, risk, serial entrepreneurs, valuation, venture capital, warrant
         Biopharmaceutical Law & Intellectual property  anti-trust, Bayh- Dole, Cohen- Boyer, Diamond vs. Chakrabarty, EPO, EST patents, electronic notebook, gene fragments, gene patents,  license, licensing, PTO, patent ..., research tools, royalty stacking, stealth patents, WIPO 

Drug discovery & development blockbuster drugs, bottlenecks, developability, drug discovery ..., drug development, drug-like, drug- likeness, druggable, high throughput, LIMS, lifestyle drugs, molecular recognition, peptidomimetic, pharmaceutical..., pharming, pipeline problem, preclinical, protein delivery, protein therapeutics, rational drug design, reverse pharmacology, reverse vaccinology,  robot..., samples..., small molecules, vaccines 
    Biopharmaceutical Assays & screening cell assays, genomic assays, high throughput screening HTS, hit, hit to lead ...,  microplate, microtiter ... microtitre ...  organotypic models, primary ..., secondary ..., screening, structure based ..., ultra HTS uHTS

Pharmaceutical biology affinity, agonist, antagonist, antibody, antisense, binding sites, chiral, efficacy, enzymes, enzymes and coenzymes, epitope, G-protein, homologue, hormone, hydrophilicity, hydrophobicity, immunotoxins,  ligand, lipophilicity, metabolite, molarity, monoclonal antibodies, PAT Process Analytical Technology,  pharmacophore, promiscuous inhibitors, receptors, recognition site, recombinant ..., solubility, substrate, vaccine
    
    Combinatorial libraries & synthesis  applied molecular evolution,  bead, binning, biomimetic ..., chemical diversity, chemical space, combinatorial ..., compound..., deconvolute, diversity ..., hit ..., linkers, microwave ..., molecular ..., multicomponent, natural products, organic synthesis, pool, privileged ..., rational library design, resins, solid phase ..., solution phase ..., space, target oriented synthesis TOS
          Drug, diagnostics approvals, clinical trials  21 CFR..., 501K, adaptive clinical trials, analyte specific reagents, biogenerics, biologics, biopharmaceuticals, CBER, CDER, CDISC, CDRH, CLIA, CRO, clinical..., clinical trials, drug, EMEA, exploratory IND, FDA, FDA draft guidelines - multiplex tests, FDAMA, fast-track, home brew, IND, IRB, me too, medical device, NCE, NDA, NME, off label, orphan products, PDUFA, pharmacovigilance, Phase I, II, III, IV, phase zero,  placebo ...,, premarket, SCT, regulatory agencies, stratification, women and minorities  

Drug safety & pharmacovigilance adverse drug event ADE, adverse drug reaction ADR, ED 50, evidence based toxicology, idiosyncratuc toxicity, molecular toxicology, pharmacoepidemiology, phase IV post marketing surveillance, post approval drug safety, predictive ADME, predictive toxicogenomics, PSURs, side effect, susceptibility, systems toxicology, therapeutic index, tox chips, toxicogenomics, toxicoinformatics, toxicology, toxicoproteomics, toxins, xenobiotic 

   Drug Targets compound ..., disease targets, drug targets, gene targeting, gene targets, GPCRs G protein coupled receptors, HDAC histone deacetylase Inhibitors,  intracellular ..., ion channels, kinases, molecular targets, nuclear hormone receptors, protein targets, target ..., target validation, tissue targeting, tractable targets

     Molecular Medicine  BSE, behavior genomics,  biomedical ..., blood, CJD, camera pill, cardiogenomics, channelopathies, chronome, chronotherapy, clinical proteomics, combination therapies, cryomedicine, cryotherapy, determinism, diagnosis, diagnostics, disease... , epidemiology, epigenomics, gene therapy, genetic medicine, genetics, genomic drugs, immunoinformatics, immunotechnology, immunotherapy, medical informatics, medical proteomics, molecular  ..., neurogenomics, normal, nutriceuticals, pathogenomics, pathology informatics, personal genomics, predictive, preventive, prognosis, psychoneuroimmunology, public health, research diagnostics, TSE, therapeutics, translational medicine, uncertainty, vCJD, world health  Patient resources  

          Cancer genomics CGAP, cancer ..., chemoprediction, cryochemotherapy, familial cancer, Gleevec, Herceptin, hereditary cancer, molecular events, molecular targets, molecular taxonomy, oncogene, oncogenomics, oncoproteomics, p53 ,,,, sporadic cancer, tumor markers, tumor suppressor genes, viral oncogene

      Genetic & genomic testing analytical sensitivity, analytical specificity, clinical sensitivity, clinical specificity, family history, genetic discrimination, genetic enhancement, genetic privacy, genetic test, genomic testing, germline mutation, "good genes", "bad genes", preconception testing, predictive testing, predisposition, preimplantation diagnosis, presymptomatic, risk communication, screening, somatic cells, susceptibility 

Pharmacogenomics  ADME ..., ADME/Tox, DME genes, DMPK, drug metabolism, drug response, ED50, endocrine disrupters, enzyme kinetics, genotype-to phenotype, hepatotoxicity, immunophenotyping, in silico pharmacology, individualized medicine, kinetic outliers, mechanism of action, metabonomics, microdosing, mode of action MOA, molecular toxicology, NIEHS,  personalized medicine, pharmacodynamics, pharmacogenetics, pharmacokinetics, pharmacoproteomics, phenotype ...,  predictive ..., reverse pharmacology, systems pharmacology, systems toxicology, target haplotype, tox- chips, toxicogenomics, toxicoproteomics, xenobiotic        

Therapeutic areas: Cancer & oncology Cardiovascular CNS & Neurology Immunology Infectious Diseases Inflammation

Bibliography
Alpha glossary index
How to look for other unfamiliar  terms